Влияние беременности на рассеянный склероз

Закрыть метаданные

Рекомендуем статьи по данной теме:

Рефлюкс-нефропатия и беременность. Российский вестник акушера-гинеколога. 2023;(6):12-18

Новая коронавирусная инфекция во II триместре беременности: перинатальные и материнские последствия. Российский вестник акушера-гинеколога. 2023;(6):34-41

Урологический сепсис в акушерской практике. Российский вестник акушера-гинеколога. 2023;(6):82-88

Особенности липидного, углеводного обмена и секреции адипонектина у беременных с абдоминальным ожирением и артериальной гипертензией. Российский вестник акушера-гинеколога. 2023;(6-2):101-106

Молекулярно-физиологические эффекты мио-инозитола и его роль в профилактике гестационного сахарного диабета у беременных с избыточной массой тела и ожирением. Российский вестник акушера-гинеколога. 2023;(6-2):120-126

Миома матки и беременность. Вопросы тактики и улучшения репродуктивных исходов. Российский вестник акушера-гинеколога. 2023;(6-2):135-141

Осложнения и исходы гестационного периода у женщин, перенесших новую коронавирусную инфекцию SARS-CoV-2 во время беременности. Российский вестник акушера-гинеколога. 2023;(6-2):167-172

Тотальное обызвествление и дислокация длительно стоящего мочеточникового катетера-стента, установленного во время беременности. Российский вестник акушера-гинеколога. 2023;(6-2):183-188

Опыт ведения беременных с хронической болезнью почек разных стадий. Российский вестник акушера-гинеколога. 2023;(6-2):189-197

Прогнозирование преэклампсии с определением четырех молекулярных подклассов omics. Проблемы репродукции. 2023;(6):41-48

Вопрос планирования беременности и возможности терапии является одним из наиболее важных у пациенток с рассеянным склерозом (РС) репродуктивного возраста. Частота отказов от планирования беременности составляет 14%. Это обусловлено многочисленными опасениями по поводу протекания беременности, ее исходов, а также возможного влияния препаратов, изменяющих течение РС (ПИТРС) на плод и вероятности передачи заболевания ребенку. В статье обсуждаются иммунологические реакции в условиях беременности при РС, которые носят протективный характер. Представлены данные по всем группам ПИТРС в отношении планирования беременности с учетом возможных рисков их влияния на фертильность и тератогенность.

Ключевые слова:

рассеянный склероз

беременность

иммунопатологические механизмы при беременности

препараты

изменяющие течение рассеянного склероза

Авторы:

Закройщикова И.В.

ФГБНУ «Научный центр неврологии»

SPIN РИНЦ: 4273-0287
Scopus AuthorID: 57203845560
ORCID: 0000-0002-2325-2302

Симанив Т.О.

ФГБНУ «Научный центр неврологии»

SPIN РИНЦ: 6243-8805
Scopus AuthorID: 56575192400
ORCID: 0000-0001-7256-2668

Земляная Д.О.

ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России

ORCID: 0009-0007-5009-8607

Тимофеева А.А.

ORCID: 0009-0002-8651-0943

Захарова М.Н.

ФГБНУ «Научный центр неврологии»

SPIN РИНЦ: 4277-2860
Scopus AuthorID: 7006679636
ResearcherID: C-4611-2012
ORCID: 0000-0002-1072-9968

Дата поступления:

17.05.2024

Дата принятия в печать:

21.05.2024

Список литературы:

Coyle PK. What Can We Learn from Sex Differences in MS? J Pers Med. 2021;11(10):1006. https://doi.org/10.3390/jpm11101006
Bonavita S, Lavorgna L, Worton H, et al. Family planning decision making in people with multiple sclerosis Front Neurol. 2021;12:620772. https://doi.org/10.3389/fneur.2021.620772
Houtchens M, Edwards N, Phillips A. Relapses and disease-modifying drug treatment in pregnancy and live birth in US women with MS. Neurology. 2018;91(17):e1570-e1578. https://doi.org/10.1212/WNL.0000000000006382
Varytė G, Zakarevičienė J, Ramašauskaitė D, et al. Pregnancy and Multiple Sclerosis: An Update on the Disease Modifying Treatment Strategy and a Review of Pregnancy’s Impact on Disease Activity. Medicina. 2020;56(2):49. https://doi.org/10.3390/medicina56020049
Якушина Т.И., Белова Ю.А. Случаи беременности у пациенток с агрессивным рассеянным склерозом на фоне приема натализумаба. Журнал неврологии и психиатрии им. С.С. Корсакова. 2019;119(2‐2):94‐97. https://doi.org/10.17116/jnevro20191192294
Spence R, Voskuhl R. Neuroprotective effects of estrogens and androgens in CNS inflammation and neurodegeneration. Front neuroendocrinol. 2012;33(1):105-115. https://doi.org/10.1016/j.yfrne.2011.12.001
Spanier J, Nashold F, Mayne C, et al. Vitamin D and estrogen synergy in Vdr-expressing CD4(+) T cells is essential to induce Helios(+)FoxP3(+) T cells and prevent autoimmune demyelinating disease. J Neuroimmunol. 2015;286:48-58. https://doi.org/10.1016/j.jneuroim.2015.06.015
Nashold F, Spach K, Spanier J, et al. Estrogen controls vitamin D3-mediated resistance to experimental autoimmune encephalomyelitis by controlling vitamin D3 metabolism and receptor expression. J Immunol. 2009;183(6):3672-3681. https://doi.org/10.4049/jimmunol.0901351
Avila M, Bansal A, Culberson J, et al. The Role of Sex Hormones in Multiple Sclerosis. Eur Neurol. 2018;80(1-2):93-99. https://doi.org/10.1159/000494262
Hayrabedyan S, Shainer R, Yekhtin Z, et al. Synthetic PreImplantation Factor (sPIF) induces posttranslational protein modification and reverses paralysis in EAE mice. Sci Rep. 2019;9(1):12876. https://doi.org/10.1038/s41598-019-48473-x
Gold SM, Sasidhar MV, Morales LB, et al: Estrogen treatment decreases matrix metalloproteinase (MMP)-9 in autoimmune demyelinating disease through estrogen receptor alpha (ERalpha). Lab Invest. 2009;89(10):1076-1083. https://doi.org/10.1038/labinvest.2009.79
Alroughani R, S. Akhtar M, Zeineddine Y, et al. Risk of relapses during pregnancy among multiple sclerosis patients. Mult Scler Relat Disord. 2019;34:9-13. https://doi.org/10.1016/j.msard.2019.06.007
Gavoille A, Rollot F, Casey R, et al. Investigating the long-term effect of pregnancy on the course of multiple sclerosis using causal inference, Neurology. 21;100(12):e1296-e1308. https://doi.org/10.1212/WNL.0000000000206774
Jokubaitis V, Spelman T, Kalincik T, et al. Predictors of long-term disability accrual in relapse-onset multiple sclerosis, Ann Neurol. 2016;80(1):89-100. https://doi.org/10.1002/ana.24682
Portaccio E, Tudisco L, Pasto L, et al. Pregnancy in multiple sclerosis women with relapses in the year before conception increases the risk of long-term disability worsening. Mult Scler. 2022;28(3):472-479. https://doi.org/10.1177/13524585211023365
Coyle PK. Management strategies for female patients of reproductive potential with multiple sclerosis: An evidence-based review. Mult Scler Relat Disord. 2019;32:54-63.
Krysko K. Patients of reproductive potential with multiple sclerosis Ther Adv Neurol Disord. 2020;13:1756286420936166.
MacDonald SC, McElrath TF, Hernandez-Diaz S, Pregnancy outcomes in women with multiple sclerosis. Am J Epidemiol. 2019;188(1):57-66. https://doi.org/10.1093/aje/kwy197
Lopez-Leon S, Geissbuhler Y, Sabido M, et al. A systematic review and meta-analyses of pregnancy and fetal outcomes in women with multiple sclerosis: a contribution from the IMI2 ConcePTION project. J Neurol. 2020;267(9):2721-2731. https://doi.org/10.1007/s00415-020-09913-1
Carta A, Zarbo I, Scoppola C, et al. Maternal multiple sclerosis is not a risk factor for neurodevelopmental disorders in offspring. Mult Scler J Exp Transl Clin. 2021;7(2):20552173211017301. https://doi.org/10.1177/20552173211017301
Wind M. multiple sclerosis and pregnancy. Eur J Obstet Gynecol Reprod Biol. 2021;260:29-36. https://doi.org/10.1016/j.ejogrb.2021.02.027
Coyle P. Management of women with multiple sclerosis through pregnancy and after childbirth. Ther Adv Neurol Disord. 2016;9(3):198-210.
Dobson R. UK consensus on pregnancy in multiple sclerosis: ‘Association of British Neurologists’ guidelines. Pract Neurol. 2019:19:106-114.
Wang Y, Wang J, Feng J. Multiple sclerosis and pregnancy: Pathogenesis, influencing factors, and treatment options. Autoimmun Rev. 2023;22(11):103449. https://doi.org/10.1016/j.autrev.2023.103449
Langer-Gould AM. Pregnancy and Family Planning in Multiple Sclerosis. Continuum (Minneap Minn). 2019;25(3):773-792).
Voge NV, Alvarez E. Monoclonal Antibodies in Multiple Sclerosis: Present and Future. Biomedicines. 2019;7(1):20. https://doi.org/10.3390/biomedicines7010020
Hellwig K, Verdun di Cantogno E, Sabidó M. A systematic review of relapse rates during pregnancy and postpartum in patients with relapsing multiple sclerosis. Ther Adv Neurol Disord. 2021;14:17562864211051012. https://doi.org/10.1177/17562864211051012
Nguyen AL, Havrdova EK, Horakova D, et al. Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study. Mult Scler Relat Disord. 2019;28:235-243. https://doi.org/10.1016/j.msard.2019.01.003
Rasmussen PV, Magyari M, Moberg JY, et al. Patient awareness about family planning represents a major knowledge gap in multiple sclerosis. Mult Scler Relat Disord. 2018;24:129-134. https://doi.org/10.1016/j.msard.2018.06.006
Kaplan TB. Management of Demyelinating Disorders in Pregnancy. Neurol Clin. 2019;37(1):17-30. https://doi.org/10.1016/j.ncl.2018.09.007
Vukusic S, Michel L, Leguy S, et al. Pregnancy with multiple sclerosis. Rev Neurol (Paris). 2021;177(3):180-194. https://doi.org/10.1016/j.neurol.2020.05.005
Hakkarainen KM, Juuti R, Burkill S, et al. Pregnancy outcomes after exposure to interferon beta: a register-based cohort study among women with MS in Finland and Sweden. Ther Adv Neurol Disord. 2020;13:1756286420951072. https://doi.org/10.1177/1756286420951072
Bove RM, Houtchens MK. Pregnancy Management in Multiple Sclerosis and Other Demyelinating Diseases. Continuum (Minneap Minn). 2022;28(1):12-33. https://doi.org/10.1212/CON.0000000000001108
Ciplea AI, Langer-Gould A, Stahl A, et al. Safety of potential breast milk exposure to IFN-β or glatiramer acetate: One-year infant outcomes. Neurol Neuroimmunol Neuroinflamm. 2020;7(4):e757.
Herbstritt S, Langer-Gould A, Rockhoff M, et al. Glatiramer acetate during early pregnancy: A prospective cohort study. Mult Scler. 2016;22(6):810-816. https://doi.org/10.1177/1352458515623366
Bove R, Sutton P, Nicholas J. Women’s Health and Pregnancy in Multiple Sclerosis. Neurol Clin. 2024;42(1):275-293. https://doi.org/10.1016/j.ncl.2023.07.004
Sandberg-Wollheim M, Neudorfer O, Grinspan A, et al. Pregnancy Outcomes from the Branded Glatiramer Acetate Pregnancy Database. Int J MS Care. 2018;20(1):9-14. https://doi.org/10.7224/1537-2073.2016-079
Kaplan S, Zeygarnik M, Stern T. Pregnancy, Fetal, and Infant Outcomes Following Maternal Exposure to Glatiramer Acetate During Pregnancy and Breastfeeding. Drug Saf. 2022;45(4):345-357. https://doi.org/10.1007/s40264-022-01168-1
Ciplea AI, Kurzeja A, Thiel S, et al. Eighteen-month safety analysis of offspring breastfed by mothers receiving glatiramer acetate therapy for relapsing multiple sclerosis — COBRA study. Mult Scler. 2022;28(10):1641-1650. https://doi.org/10.1177/13524585221083982
Hellwig K, Rog D, McGuigan C, et al. Interim Analysis of Pregnancy Outcomes After Exposure to Dimethyl Fumarate in a Prospective International Registry. Neurol Neuroimmunol Neuroinflamm. 2021;9(1):e1114. https://doi.org/10.1212/NXI.0000000000001114
Ciplea AI, Datta P, Rewers-Felkins K, et al. Dimethyl fumarate transfer into human milk. Ther Adv Neurol Disord. 2020;13:1756286420968414. https://doi.org/10.1177/1756286420968414
Leroy C, Rigot JM, Leroy M, et al. Immunosuppressive drugs and fertility. Orphanet J Rare Dis. 2015;10:136. https://doi.org/10.1186/s13023-015-0332-8
Guarnaccia JB, Cabot A, Garten LL, et al. Teriflunomide levels in women whose male sexual partner is on teriflunomide for relapsing multiple sclerosis. Mult Scler Relat Disord. 2022;57:103347. https://doi.org/10.1016/j.msard.2021.103347
Krysko KM, Dobson R, Alroughani R, et al. Family planning considerations in people with multiple sclerosis. Lancet Neurol. 2023;22(4):350-366. https://doi.org/10.1016/S1474-4422(22)00426-4
Vukusic S, Coyle PK, Jurgensen S, et al. Pregnancy outcomes in patients with multiple sclerosis treated with teriflunomide: Clinical study data and 5 years of post-marketing experience. Mult Scler. 2020;26(7):829-836. https://doi.org/10.1177/1352458519843055
Varytė G, Arlauskienė A, Ramašauskaitė D. Pregnancy and multiple sclerosis: an update. Curr Opin Obstet Gynecol. 2021;33(5):378-383. https://doi.org/10.1097/GCO.0000000000000731
Zhen Y. Natalizumab, Fingolimod and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis. Neurology. 2021;96(24):e2989-e3002. https://doi.org/10.1212/WNL.0000000000012084
Doriana L. Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2022;34:34-38. https://doi.org/10.1136/jnnp-2022-329657
Vukusic S, Carra-Dalliere C, Ciron J, et al. Pregnancy and multiple sclerosis: 2022 recommendations from the French multiple sclerosis society. Mult Scler. 2023;29(1):11-36. https://doi.org/10.1177/13524585221129472
Undine P. Drug and Neurofilament Levels in Serum and Breastmilk of Women With Multiple Sclerosis Exposed to Natalizumab During Pregnancy and Lactation. Front Immunol. 2021;12:715195. https://doi.org/10.3389/fimmu.2021.715195
Karlsson G, Francis G, Koren G, et al. Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis. Neurology. 2014;82(8):674-680. https://doi.org/10.1212/WNL.0000000000000137
Pauliat E, Onken M, Weber-Schoendorfer C, et al. Pregnancy outcome following first-trimester exposure to fingolimod: A collaborative ENTIS study. Mult Scler. 2021;27(3):475-478. https://doi.org/10.1177/1352458520929628
Callens A, Leblanc S, Le Page E, et al. Disease reactivation after fingolimod cessation in Multiple Sclerosis patients with pregnancy desire: A retrospective study. Mult Scler Relat Disord. 2022;66:104066. https://doi.org/10.1016/j.msard.2022.104066
Bianco A, Lucchini M, Totaro R, et al. Disease Reactivation after Fingolimod Discontinuation in Pregnant Multiple Sclerosis Patients. Neurotherapeutics. 2021;18(4):2598-2607. https://doi.org/10.1007/s13311-021-01106-6
Rowles WM, Hsu WY, McPolin K, et al. Transitioning From S1P Receptor Modulators to B Cell-Depleting Therapies in Multiple Sclerosis: Clinical, Radiographic, and Laboratory Data. Neurol Neuroimmunol Neuroinflamm. 2022;9(4):e1183. https://doi.org/10.1212/NXI.0000000000001183
Almas S, Vance J, Baker T, Hale T. Management of Multiple Sclerosis in the Breastfeeding Mother. Mult Scler Int. 2016;2016:6527458. https://doi.org/10.1155/2016/6527458
Giovannoni G, Soelberg Sorensen P, Cook S, et al. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study. Mult Scler. 2018;24(12):1594-1604. https://doi.org/10.1177/1352458517727603
Dost-Kovalsky K, Thiel S, Ciplea AI, et al. Cladribine and pregnancy in women with multiple sclerosis: The first cohort study. Mult Scler. 2023;29(3):461-465. https://doi.org/10.1177/13524585221131486
Giovannoni G, Galazka A, Schick R, et al. Pregnancy Outcomes During the Clinical Development Program of Cladribine in Multiple Sclerosis: An Integrated Analysis of Safety. Drug Saf. 2020;43(7):635-643. https://doi.org/10.1007/s40264-020-00948-x
Datta P, Ciplea AI, Rewers-Felkins K, et al. Cladribine transfer into human milk: A case report. Mult Scler. 2021;27(5):799-801. https://doi.org/10.1177/1352458520912173
Khan E, Kagzi Y, Elkhooly M, et al. Disease modifying therapy and pregnancy outcomes in multiple sclerosis: A systematic review and meta-analysis. J Neuroimmunol. 2023;383:578178. https://doi.org/10.1016/j.jneuroim.2023.578178
Steingo B, Al Malik Y, Bass AD, et al. Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223. J Neurol. 2020;267(11):3343-3353. https://doi.org/10.1007/s00415-020-09983-1
Li Z, Richards S, Surks HK, Jacobs A, et al. Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis. Clin Exp Immunol. 2018;194(3):295-314. https://doi.org/10.1111/cei.13208
Oh J, Achiron A, Celius EG, et al. Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 years. Mult Scler Relat Disord. 2020;43:102146. https://doi.org/10.1016/j.msard.2020.102146

Закрыть метаданные